glutathione and autoimmune is one of the body’s major antioxidants, research suggests it may help support cellular health and reduce oxidative stress, which is why it’s getting more attention in areas like Glutathione, GST Genotypes and Susceptibility

They'll serve different niches: CagriSema Will Dominate: Patients familiar with Wegovy brand Those wanting proven semaglutide component People with type 2 diabetes (strong REIMAGINE data) Earlier availability (mid-2027) Retatrutide Will Dominate: Patients needing maximum weight loss (BMI 40) Those with multiple complications (OA + OSA + obesity) People who failed CagriSema Willingness to wait for highest efficacy Tirzepatide (Zepbound) Will Remain Relevant: Already available NOW Proven safety with 22.5% weight loss Lower cost than either new option Established insurance coverage The High-Dose CagriSema Wildcard Novo Nordisk announced plans for CagriSema 2.4mg/7.2mg trials starting late 2026tripling the cagrilintide dose

it requires a bit of personal experimentation

We wished to review the current adherence to secondary prevention strategies in a tertiary stroke centre

doi: 10.1016/j.algal.2019.101617 29

Gastrointestinal Models Sikiric et al

China Life Sciences 67, 19151927